This is Monday's deep dive on Lp(a). On Friday June 12 we named it as one of three tests to ask for at your next blood draw. If you have not booked the draw yet, this is your reminder and the why. If you have and the number came back, this is what to do with it.
Genetics accounts for roughly 15 percent of your healthspan. The other 85 percent is what you do with your body, your kitchen, your sleep, your training, your stress. Lp(a) sits on the genetic side of that ledger. It is a cholesterol-carrying particle nearly identical to LDL but with an extra genetic marker bolted onto it, which makes it stickier, more inflammatory, and more likely to embed in artery walls than regular LDL. Your level is set close to birth, driven roughly 80 to 90 percent by the LPA gene, and stays roughly stable for the rest of your life. You get one number, once, and it is your number forever.
Which is exactly why the 85 percent side of the ledger matters more, not less, if your Lp(a) comes back high. You cannot move the genetic number. So every lifestyle and metabolic lever you can move counts double. That reframe is the whole point of today's piece.
What your standard panel measures
Total cholesterol
LDL-C (calculated)
HDL-C
Triglycerides
The cholesterol you can move.
What it does not include
Lp(a)
ApoB
hs-CRP
Lipid particle number
The cholesterol you were born with.
The evidence
The consensus that every adult should know their Lp(a) at least once has been building for a decade and became formal in 2026. The European Society of Cardiology consensus statement led by Florian Kronenberg in the European Heart Journal, 2022, was the first major society document to argue that Lp(a) should be measured at least once in every adult's lifetime. The 2026 ACC/AHA Dyslipidemia Guideline, published in Circulation in March, made it Class I universal. Every adult, at least once. That is the strongest recommendation level the guideline system produces.
The prevalence justifies the recommendation. Roughly one in five adults globally carries a clinically elevated Lp(a) level, above 50 mg/dL in mass units or 125 nmol/L in molar units. Prevalence sits in the same 20 percent band in both US and Australian cohorts, and runs higher in adults of African ancestry. Most carriers do not know it, because a standard lipid panel does not include the marker. The gap is not a diagnostic mystery. It is a testing gap.
The mechanism explains why the number matters even when standard LDL looks fine. Lp(a) contributes an independent, additive risk of atherosclerosis, aortic valve stenosis, and thrombosis. In cohort data, adults with Lp(a) above 100 mg/dL carry roughly two to three times the risk of a coronary event over a lifetime compared to adults with Lp(a) below 30, holding other lipids constant. The number is the risk that hides behind a "normal" cholesterol result.
Set at birth. Lower everything else.
The card shows three numbers: 1 in 5 (Australian adults with clinically elevated Lp(a)), 90% (Lp(a) determined by the LPA gene at birth), 1 (test, once, then never again).
If your number came back high
The most important thing to know about Lp(a) is what you cannot do about it.
Diet does not move Lp(a). Weight loss does not move it. Exercise does not move it. Statins do not move it and in some patients slightly raise it. These interventions are all worth doing, they just move the other lipids and do not touch this one. The most current reviews of the lifestyle literature confirm the picture that has held for two decades: Lp(a) is essentially fixed by genetics.
The pharma reality is modest and improving. PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by roughly 20 to 30 percent on average. The FOURIER trial with evolocumab showed a median Lp(a) reduction of 27 percent at 48 weeks, though the range was wide (6 to 47 percent depending on the individual). Meaningful but not transformative.
The Lp(a)-specific therapies in late-stage trials are transformative. Olpasiran, an Amgen siRNA molecule reported in the New England Journal of Medicine in 2022, lowered Lp(a) by 70 to 100 percent depending on dose in phase 2. Pelacarsen from Ionis, an antisense oligonucleotide currently in the phase 3 Lp(a)HORIZON outcomes trial, reduces Lp(a) by roughly 80 percent. If either or both prove they reduce cardiovascular events in the phase 3 readouts, Lp(a) becomes the next lever the way LDL became one after the statins landed.
The strategic implication for you, right now, if your Lp(a) is above 50 mg/dL. You cannot move Lp(a) much. So you lower everything else. ApoB below 80 mg/dL. hs-CRP below 1.0 mg/L. Blood pressure below 120/80. Fasting glucose in the healthy band. Each of these levers is real, each is well-studied, and together they neutralise a meaningful fraction of the risk that the un-moveable Lp(a) contributes. This is the frame the strongest lipidologists argue for and it is the frame the 2026 guideline endorses.
What This Means For You
If you have not tested yet, book the draw this week. In the US, the direct-to-consumer route is the fastest path. Ulta Lab Tests offers a standalone Lp(a) blood test for roughly $56 with no doctor's order, using any of the 2,100 Quest Diagnostics draw sites nationwide; results in 24 to 72 hours. Function Health bundles Lp(a) into its $499 annual panel that also picks up ApoB, hs-CRP and roughly 100 other markers, which is the more complete but pricier route. In Australia, MediTests runs a standalone Lp(a) for $89 through Healius collection centres nationwide, and i-Screen bundles it into an advanced lipid panel for roughly $180. One tube of blood. One number. Then never again.
If your number came back and it is high, the action is not a supplement, not a diet, not a new gym plan. The action is a clinician conversation about lowering ApoB, hs-CRP and blood pressure aggressively. For the deepest single read on why Lp(a) is the number the wellness internet has quietly declined to explain, the Sniderman ApoB framework paper in JAHA 2022 is the primer. It reads for the intelligent lay reader and covers the lower-everything-else math.
Score your cardiovascular risk before the draw. The Healthspan Score is the five-minute assessment that surfaces which of the four levers you should push hardest on this year. ApoB, hs-CRP, blood pressure, glucose. Free, no blood draw.
Wednesday Preview
The pill you probably have not been offered, that you probably should not take if you are low-risk, that saves lives in the population where it belongs. Statins for primary prevention. The absolute-versus-relative-risk math the pharma advertising elides. And where the strongest current lipidologists actually draw the line. Wednesday.
Reply and tell us what your Lp(a) number came back at. We read every one. Anonymous.
Until Wednesday.
Longevity Daily · The Building Decades
Share this edition with someone you love.
P.S. If your Lp(a) comes back below 30 mg/dL, you are done. Never test again.